The LEGATO-HD Study
A randomized, double blind research study to see what effect the investigational drug, laquinimod, has on movement, thinking, and behavior, compared to placebo (a sugar pill), in people with Huntington disease after 52 weeks of receiving either laquinimod or placebo.
What is the LEGATO-HD Study?
The purpose of the LEGATO-HD trial is to see what effect different doses of an investigational drug called laquinimod may have on people with HD. In addition, information will be collected about the safety and possible side effects of laquinimod in people with HD.
This is a placebo-controlled trial, with participants randomly assigned to receive one of three different doses of laquinimod, or placebo (sugar pill). Everyone will receive the same number of capsules (3, taken together once a day), and neither participants nor their trial doctors will know to which group they are assigned.
Who is running the LEGATO-HD Trial?
LEGATO-HD is a joint collaboration between the Huntington Study Group (HSG), the European Huntington’s Disease Network (EHDN) and Teva Branded Pharmaceutical Products R&D Inc. 400 people are expected to take part in the LEGATO-HD Study at approximately 36 trial sites across North America and Europe. Participants will receive laquinimod or placebo in the form of capsules, for 52 weeks (12 months).
The trial is sponsored (financially supported) by Teva Branded Pharmaceutical Products R&D Inc.
Who is eligible to participate in the LEGATO -HD trial?
You may be eligible to participate in the study if you meet the following requirements:
How can I learn more about the LEGATO-HD trial?
You are between the ages of 18 and 55
You are able and willing to provide written informed consent prior to any trial-related procedure
You are willing to provide a blood sample for genetic analyses
You are willing and able to take medication by mouth and cooperate with trial procedures
You are able to walk by yourself or with assistance and able to travel to the trial center, and judged by the trial physician as likely to be able to travel for the duration of the trial
You have a caregiver willing to attend trial visits with you
You not been treated with chemotherapy or drugs that affect your immune system
You are not taking tetrabenazine (Xenazine)